Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07006792 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

Name: A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — clinical trial record (NCT07006792)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ADsolve

StatusActive, Not Recruiting

PhasePhase 4

SponsorEli Lilly and Company

Started2025-06-16

View on ClinicalTrials.gov ↗

The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.

Amendment history 4 changes detected by DataLookout

2026-05-23

Trial status changed: Recruiting → Active, Not Recruiting

2026-05-23

Enrollment increased: 200 → 233 participants

2026-05-23

Primary completion pushed: 2026-04 → 2026-05-14

2026-04-18

Trial sites reduced: 71 → 66 locations

Trial Details

NCT Number	NCT07006792
Lead Sponsor	Eli Lilly and Company
Conditions	Atopic Dermatitis
Enrollment	233 participants
Start Date	2025-06-16
Primary Completion	2026-05-14 (estimated)
Study Completion	2026-09 (estimated)
Updated on ClinicalTrials.gov	2026-05-22